Sphinogosine-1 -phosphate receptor modulators for treatment of cardiopulmonary disorders

A method for the treatment of a patient afflicted with a disease selected from the group consisting of cardiopulmonary disease, sepsis, and systemic sclerosis, comprising administering to the patient a compound of formula (I) or a pharmaceutically acceptable salt thereof:

• wherein
• Ar1 is a phenyl optionally mono- or multi-substituted with up to three substituents selected from the group consisting of (C1-C4)alkyl, halo, halo(C1-C4)alkyl, OH, and (C1-C4)alkoxy;
• Ar2 is phenyl or pyridyl, wherein Ar2 is optionally substituted with up to three substituents selected from the group consisting of (C1-C4)alkyl, monohydroxy(C1-C4)alkoxy, halo, cyano, (C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(CH2)0-2, halo(C1-C4)alkyl, OH, monohydroxy(C1-C4)alkyl, NR2C(═O)(CH2)0-2O(CH2)0-2, NR2C(═O)(CH2)0-2, (C1-C4)C(═O)N(R), (5- to 10-membered)heterocyclyl, (5- to 10-membered) heteroaryl;
• Ar3 is pyridyl optionally substituted with up to three substituents selected from the group consisting of (C1-C4)alkyl, (C2-C4)alkenyl, halo, halo(C1-C4)alkyl, OH, (C1-C4)alkoxy, (C1-C6)alkoxycarbonyl(CH2)0-2, carboxy(CH2)0-2, monohydroxy(C1-C4)alkyl, NR2(CH2)0-2, (C3-C10)cycloalkyl;
• R′ is H,
• X is N(R) and L is C(═O);
• and
• R is H or (C1-C4)alkyl.